Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vascular endothelial growth factor receptor 1, 2, and 3 refer to a family of three distinct, but structurally and functionally related, receptor tyrosine kinases. While each receptor has unique primary roles (e.g., VEGFR1 in decoy signaling and monocyte chemotaxis, VEGFR2 in angiogenesis, VEGFR3 in lymphangiogenesis), they collectively mediate various aspects of vascular and lymphatic development, maintenance, and pathological processes. This entry is considered 'incorrect' for structured extraction as these are individually targetable proteins that should be treated separately for accurate annotation and data integrity.
Drugs targeting these receptors primarily act through inhibition of VEGF-ligand binding, thereby preventing receptor activation, or by directly inhibiting the receptor's intrinsic tyrosine kinase activity, and in some cases, by sequestering ligands.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vascular endothelial growth factor receptor 1, 2, 3 (VEGFRs).